



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 731 032 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

**13.12.2006 Bulletin 2006/50**

(51) Int Cl.:

**A01K 67/027** <sup>(2006.01)</sup> **C07K 16/18** <sup>(2006.01)</sup>  
**C12N 15/09** <sup>(2006.01)</sup>

(21) Application number: **05727975.4**

(86) International application number:

**PCT/JP2005/006298**

(22) Date of filing: **31.03.2005**

(87) International publication number:

**WO 2005/094572 (13.10.2005 Gazette 2005/41)**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

- **KAMADA, Nobuo,**  
**CHUGAI SEIYAKU KABUSHIKI KAISHA**  
Gotenba-shi,  
Shizuoka 4120038 (JP)
- **JISHAGE, Kou-ichi,**  
**CHUGAI SEIYAKU KABUSHIKI KAISHA**  
Gotenba-shi,  
Shizuoka 4120038 (JP)

(30) Priority: **31.03.2004 JP 2004107669**

(71) Applicant: **CHUGAI SEIYAKU KABUSHIKI KAISHA**  
**Tokyo, 115-8543 (JP)**

(74) Representative: **Vossius & Partner**  
**Siebertstrasse 4**  
**81675 München (DE)**

(72) Inventors:

- **KODAMA, Tatsuhiko**  
**1540002 (JP)**
- **YAMADA, Yoshiki,**  
**CHUGAI SEIYAKU KABUSHIKI KAISHA**  
Gotenba-shi,  
Shizuoka 4120038 (JP)

(54) **NONHUMAN ANIMALS FOR ANTIBODY PRODUCTION, AND METHODS AND SYSTEMS FOR PRODUCING ANTIBODIES USING SUCH ANIMALS**

(57) Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transgenic animals, and even when genes encoding soluble proteins were used, immunotolerance against the full-length membrane proteins could be induced.

Moreover, by expressing the background antigen membrane proteins as soluble proteins inside the bodies of transgenic animals, unfavorable phenotypes that appear when the full-length membrane proteins are expressed could be avoided, and such animals were made widely available as immunized animals.

**EP 1 731 032 A1**

**Description**Technical Field

**[0001]** The present invention relates to systems and such for antibody production in which animals are immunized with immunogens comprising, other than target antigens, background antigens to produce antibodies specific to the target antigens, and particularly relates to systems and such in which immunized animals carry genes encoding soluble forms of membrane proteins so that immunotolerance against the background antigens comprising the membrane proteins is induced in the immunized animals.

Background Art

**[0002]** Antibody production is very difficult when it is difficult to express and purify the target antigens necessary to produce the antibodies. This tendency is pronounced for membrane proteins. Therefore, a technique has been developed which uses proteins that are difficult to express or purify, such as seven-transmembrane proteins, as antigens by expressing the antigenic proteins on the membrane surface of the *Autographa californica* nuclear polyhedrosis virus (AcNPV), which belongs to *Baculovirus* (Non-Patent Document 1).

**[0003]** However, although baculovirus expression systems are useful as expression systems for various proteins comprising membrane proteins, there are many gp64 membrane proteins (Non-Patent Documents 2 and 3) on the surface of baculoviruses, and these contaminate the expression products obtained from baculovirus expression systems. gp64 is a 64-kDa protein, a major component of the surface of budding viruses, and known to be a protein involved in envelope fusion at low pH. This gp64 is more easily recognized as non-self than human-derived antigenic proteins, and when gp64 contaminates immunogens, antibodies are produced more readily against gp64 than against the target antigens. Therefore, when preparing immunogens using a baculovirus expression system, it is difficult to produce and obtain specific antibodies against antigenic proteins (Non-Patent Document 4). As a means to solve this problem, the present inventors generated gp64 transgenic mice (hereinafter referred to as "Tgm"). Before their immune system develops, these Tgm (hereinafter referred to as "gp64Tgm") carry an exogenous gp64 in the same way as the endogenous genes. Therefore, these Tgm show immunotolerance against gp64, just as they do for the endogenous genes. Thus they recognize target antigenic proteins expressed using baculovirus, enabling the advantageous production of specific antibodies (Patent Document 1).

**[0004]** However, the gp64Tgm showed a phenotype with no testes development nor sperm formation. Therefore, the maintenance of the strain was restricted to females, and although the strain could be maintained, efficient breeding was not possible. In addition, there were some difficulties when producing crossbred animals by crossing with other knockout mice or Tgm. [Patent Document 1] WO 03/104453.

[Non-Patent Document 1] Biotechnology, vol.13, 1079-84, 1995.

[Non-Patent Document 2] Journal of Immunological Methods, vol.234, 123-135, 2000.

[Non-Patent Document 3] Journal of Virology, vol.70, No.7, 4607-4616, 1996.

[Non-Patent Document 4] Journal of Virology, vol.69, No.4, 2583-2595, 1995.

Disclosure of the InventionProblems to be Solved by the Invention

**[0005]** As described above, the aforementioned gp64Tgm are useful as animals to be immunized for producing specific antibodies against proteins expressed using baculoviruses, but gp64Tgm had a problem of being infertile. Therefore, an objective of the present invention is to generate even more useful Tgm without unfavorable phenotypes such as inhibited testes development, and to provide methods and such for producing antibodies using these novel Tgm, so that the expression and maintenance of such exogenous membrane proteins in transgenic animals are enabled.

Means to Solve the Problems

**[0006]** The present inventors predicted that the inhibition of testes development is caused by gp64 expression on cell membranes in the testes. Soluble gp64 (hereinafter referred to as "sgp64"), produced by deleting the transmembrane region from (full-length) gp64, was linked to the pCAGGS vector (Gene, vol. 108, 193-200, 1991) to construct an sgp64 expression vector (hereinafter referred to as "pCAG-sgp64 vector"). When sgp64Tgm were produced by introducing this vector into mice, male Tgm maintained their fertility, and the present inventors successfully overcame the conventional problem of inhibited testes development. These sgp64Tgm and control non-transgenic mice were immunized using a

budding baculovirus, sera were collected, and the presence of immunotolerance against gp64 was examined. As a result, antibodies against gp64 were produced in control non-transgenic mice, but were hardly detected in sgp64Tgm. In other words, the present inventors were able to avoid the male infertility observed in conventional gp64Tgm by using sgp64, and were able to establish transgenic mice effective for producing antibodies using antigens expressed in baculovirus. The present invention is based on these findings, and more specifically, relates to the following:

- (1) a nonhuman animal carrying a gene encoding a soluble form of a membrane protein;
- (2) the nonhuman animal of (1), which is a transgenic animal into which a gene encoding a soluble protein (also referred to as "soluble form protein" in the present application) has been introduced exogenously;
- (3) the nonhuman animal of (2), which is a progeny of the transgenic animal into which a gene encoding a soluble protein has been introduced exogenously;
- (4) the nonhuman animal of any one of (1) to (3), wherein the membrane protein is derived from a virus;
- (5) the nonhuman animal of (4), wherein the virus is a baculovirus;
- (6) the nonhuman animal of (5), wherein the membrane protein is gp64;
- (7) the nonhuman animal of (6), wherein the soluble protein is gp64 that lacks a transmembrane region;
- (8) the nonhuman animal of (6), wherein the soluble protein comprises an extracellular region of gp64;
- (9) the nonhuman animal of any one of (1) to (8), wherein the nonhuman animal is a mouse;
- (10) the nonhuman animal of any one of (6) to (9), wherein the male is fertile;
- (11) a method for producing an antibody, which comprises the steps of:

immunizing the nonhuman animal of any one of (1) to (10) with an immunogen comprising a target antigen; and obtaining an antibody against the target antigen or a gene encoding such an antibody;

- (12) the method of (11) for producing an antibody, wherein the immunogen is a viral particle or a portion thereof;
- (13) the method of (12) for producing an antibody, wherein the virus is a baculovirus;
- (14) the method of any one of (11) to (13) for producing an antibody, wherein the target antigen is a membrane protein; and
- (15) a system for producing an antibody, which comprises the nonhuman animal of any one of (1) to (10).

**[0007]** To facilitate the understanding of the present invention, the meaning of some of the presupposed terms are explained.

**[0008]** In the present invention, the term "target antigen" denotes antigens recognized by subject antibodies. The target antigens can be selected from any substance having antigenicity. Specifically, proteins, sugar chains, lipids, inorganic substances, or such are known as substances showing antigenicity. The target antigens may be naturally occurring or artificially synthesized. The artificially synthesized target antigens comprise recombinant proteins prepared by genetic engineering technology, and many kinds of chemically-synthesized organic compounds.

**[0009]** The term "background antigen" denotes substances comprising antigenic determinants for which antibody generation is not desired, or denotes the antigenic determinants themselves. For example, any antigenic substance that is not a target antigen, but which contaminates the target antigen, is a background antigen. Typical background antigens are proteins contaminated within crudely purified target antigens. More specifically, host cell-derived proteins in a recombinant protein are examples of background antigens. The term "background antigen" may also be defined to mean antigens that are comprised within an immunogen for inducing subject antibody generation, and that induce production of a non-subject antibody. Generally, a background antigen is thought to indicate an antigenic substance other than a target antigen. In the present invention, however, antigenic determinants present on target antigen molecules may also be comprised in the background antigens. For example, if an antigenic determinant for which antibody generation is undesired is present on a target antigen molecule, the antigenic determinant is comprised in the background antigens of the present invention.

**[0010]** The term "immunotolerance" denotes a condition in which an immune response, specific to an antigen that is an immunotolerance target (an immunotolerance antigen), is lost or decreased. When the level of a subject's immune response to an immunotolerance antigen is reduced compared to that of a normal immunized animal, the subject can be regarded to comprise immunotolerance against the immunotolerance antigen. For example, when the amount of an antibody generated against an immunotolerance antigen is decreased in response to the administration of an immunotolerance antigen, the level of immune response is then considered to be low.

#### Brief Description of the Drawings

**[0011]**

Fig. 1-a shows the nucleotide sequence of the soluble gp64 gene used in the Examples. Nucleotides 1 to 720 are shown.

Fig. 1-b shows the nucleotide sequence of the soluble gp64 gene used in the Examples. Nucleotides 721 to 1486 are shown.

Fig. 2 shows a schematic map of the pCAG-sgp64 vector.

Fig. 3 is a photograph showing a Western blot with anti-mouse IgG to confirm that immunotolerance against gp64 is induced in sgp64Tgm.

#### Best Mode for Carrying Out the Invention

**[0012]** The present invention provides transgenic animals useful for producing antibodies against target antigens when using immunogens that have, other than the target antigens, membrane proteins contaminating as background antigens, and also provides methods and systems for antibody production using such transgenic animals.

**[0013]** As described above, in the present invention, the background antigens are membrane proteins. Examples of cases where membrane proteins contaminate as background antigens comprise the contamination of membrane proteins derived from host organisms used to prepare target antigens, and the contamination of membrane proteins derived from viruses used for the expression systems. For example, when the target antigen is expressed together with viral vector-derived membrane proteins, such as the case in which a baculovirus expression system is used to prepare a membrane protein as a target antigen, large quantities of vector-derived membrane proteins contaminate as background antigens.

**[0014]** Herein, "membrane protein" ordinarily means a protein that constitutes a biological membrane, and for example, it refers to a protein embedded in a biological membrane; however, in the present invention, it also comprises proteins linked to a cell membrane surface via an anchor and the like, such as GPI-anchored proteins. Moreover, virus-derived membrane proteins ordinarily refer to proteins that constitute the envelope of budding viruses. For example, in baculoviruses, a protein called gp64 corresponds to a membrane protein. The structure of many of these membrane proteins comprises a region embedded in the cell membrane (transmembrane region), a region exposed on the outer side of the cell membrane (extracellular region), and a region positioned on the inner side of the cell membrane (intracellular region). Functionally, membrane proteins comprise proteins constituting membranes, receptors, proteins involved in signal transduction and the like such as transporters, and proteins such as membrane enzymes that perform specific reactions. Therefore, when such an exogenous membrane protein is introduced into an animal to be immunized, its expression in any biological membrane of the animal to be immunized will not only induce immunotolerance, but may also confer other unfavorable characteristics. For example, the problem of male infertility arises in mice into which the baculovirus-derived membrane protein gp64 has been introduced.

**[0015]** In the nonhuman animals of the systems for antibody production of the present invention, immunotolerance is induced against virus-derived membrane proteins that may be contaminating immunogens as the aforementioned background antigens. For example, nonhuman animals in which immunotolerance against baculovirus-derived membrane protein gp64 has been induced are used as the immunized animals when using immunogens prepared with the baculovirus expression systems. In the past, methods where immunized animals carry a gene encoding a full-length membrane protein, which is a background antigen, had been developed as methods for inducing immunotolerance; however, in the present invention, nonhuman animals carry a gene encoding a solubilized membrane protein (hereinafter referred to as a "soluble protein").

**[0016]** A "soluble protein" (also referred to as "soluble form protein" in the present application) refers to a membrane protein originally expressed on a biological membrane (insoluble protein) that has been modified so that it may be expressed outside a biological membrane. As described above, since membrane proteins comprise those that function as receptors or transporters that may be involved in signal transduction and those that function as switches in the living body, such as membrane enzymes, when such membrane proteins are expressed in the biological membranes of the animals to be immunized, they not only induce immunotolerance against background antigens in the animals to be immunized but can also confer unfavorable characteristics to the animals. To avoid such inconveniences, in the present invention, the membrane proteins are converted to soluble forms so that they may be expressed outside biological membranes. In addition, compared to conventional methods that use full-length membrane proteins and express them on biological membranes, which are localized sites, the present invention allows membrane proteins to be expressed systemically in the cytoplasm in their soluble form; therefore, the efficiency of immunotolerance induction is expected to improve.

**[0017]** In the present invention, genetic engineering methods for modifying genes encoding membrane proteins are used to modify the membrane proteins into soluble forms. An example of a genetic engineering method for solubilizing membrane proteins is the deletion of a transmembrane region. The degree of transmembrane region deletion may be deletion of a portion of the transmembrane region, or deletion of the entire transmembrane region, so long as the membrane protein can be expressed extracellularly. Since transmembrane regions generally form an  $\alpha$ -helical structure comprising 20 to 30 amino acids, proteins can also be solubilized by introducing mutations to change this structure.

**[0018]** As regions other than the transmembrane region, there are the intracellular region and the extracellular region; however, when modifying membrane proteins into soluble proteins, the intracellular region is not necessary, and soluble proteins may be limited to the extracellular region alone, which is equipped with antigenic determinants that can induce immunotolerance. Moreover, the extracellular region may also be limited to regions that may induce immunotolerance, such as regions that maintain antigenicity and are equipped with antigenic determinants capable of inducing immunotolerance against membrane proteins.

**[0019]** In addition to deleting the transmembrane region and such from membrane proteins and such, the aforementioned soluble proteins may comprise a chimeric protein into which other peptides and such have been added or inserted. The peptides added/inserted to the chimeric proteins may be antigenic determinants of other background antigens (these "other background antigens" may or may not be membrane proteins). Thus, immunotolerance against multiple background antigens can be induced by equipping a single protein with antigenic determinants against multiple background antigens.

**[0020]** As an example of the construction of a soluble protein, the case of baculovirus membrane protein gp64 will be used and explained. gp64 is encoded by the DNA sequence of SEQ ID NO: 1; its transmembrane region is encoded by nucleotides 1465 to 1515, and its extracellular region is encoded by nucleotides 1 to 1464. Therefore, to solubilize gp64, the aforementioned transmembrane region can be deleted, the sequence encoding the amino acids responsible for the  $\alpha$ -helix structure can be substituted with that of other amino acids, or so forth. Also, the entire protein, comprising 488 amino acid residues that are encoded by nucleotides 1 to 1464 shown in SEQ ID NO: 3, may be used for the aforementioned extracellular region, or the length of the extracellular region can be shortened to within a range that can maintain cross-reactivity with gp64 and induce immunotolerance against gp64. Furthermore, one or more modifications such as amino acid deletion, substitution, addition, or insertion can be made to the amino acid sequence of the extracellular region of gp64 (amino acid residues 1 to 488 in the amino acid sequences of SEQ ID NOs: 1 to 3), within a range that allows the induction of immunotolerance against gp64 in the immunized animals described below.

**[0021]** In the present invention, immunotolerance is induced by making nonhuman animals carry genes encoding such soluble proteins. Nonhuman animals that can be used in the present invention comprise, for example, monkeys, pigs, dogs, rats, mice, and rabbits. For example, rodents such as rats, mice, and hamsters are preferable as nonhuman animals. To induce immunotolerance by preparing transgenic animals, it is advantageous to use nonhuman animals which mature fast and for which gene manipulation technologies have been established, such as rodents. Mice in particular are nonhuman animals that meet these requirements at a high level.

**[0022]** Nonhuman animals carrying a gene encoding the aforementioned soluble protein can be obtained by producing transgenic animals into which a gene encoding the soluble protein has been introduced as an exogenous gene. For example, transgenic mice can be produced according to known methods (Proc. Natl. Acad. Sci. USA 77: 7380-7384 (1980)). Specifically, subject genes are introduced into mammalian totipotent cells, and then the cells are brought up into individuals. A subject transgenic mouse can be obtained from the individuals thus obtained by screening for individuals in which the introduced gene has been integrated into both somatic cells and germ cells. Fertilized eggs, early embryos, and cultured cells with multipotency such as ES cells, and such, can be used as the totipotent cells for introducing a gene. More specifically, they can be produced by the method in the Examples described below.

**[0023]** The nonhuman animals carrying a gene encoding a soluble protein of the present invention may be offspring of the above-mentioned transgenic animals. Once transgenic animals are established, transmission to the offspring of the characteristics (in the present invention, the characteristic of immunotolerance) caused by the introduced gene is usually easy. However, since the previously developed transgenic animals into which baculovirus gp64 has been introduced had developed the problem of male infertility, it was difficult to efficiently reflect the characteristic of immunotolerance in their offspring. On the other hand, in the present invention, by producing transgenic animals using genes encoding soluble forms of the membrane proteins, the expression of unfavorable characteristics found in the transgenic animals into which genes encoding full-length membrane proteins have been introduced was avoided. As one example, the use of a gene encoding a soluble form of the baculovirus gp64 protein in the production of transgenic animals has made it simple to transmit characteristics to the offspring by maintaining male fertility and efficient reproduction. Since transgenic animals carrying soluble gp64 can reproduce efficiently, and their offspring also carry the characteristic of immunotolerance, they become useful as animals to be immunized for antibody production and such, as described below. Therefore, by making nonhuman animals carry a gene encoding a soluble protein rather than a full-length membrane protein, immunized animals in which immunotolerance has been induced against that membrane protein can be more widely and easily used.

**[0024]** Nonhuman animals carrying a gene encoding a soluble form of a membrane protein of the present invention can be produced based on gene deficient animals in which the target antigenic protein is deleted (so-called knockout animals). Nonhuman animals carrying a gene encoding the soluble form of the membrane protein may also be produced by crossing background antigen-expressing transgenic animals with such target antigenic protein knockout animals. This enables the characteristics of background antigen expression and target antigenic protein deletion to be conferred to the nonhuman animals. In such animals carrying both characteristics, immunotolerance against background antigens

is induced, while the target antigen is more readily recognized as a foreign substance since the animals do not innately carry the target antigen; therefore, the desired antibodies can be obtained efficiently.

**[0025]** In the nonhuman animals of the present invention, in which immunotolerance against background antigens is induced, suppression of antibody production against all background antigens that may be comprised in an immunogen is not necessarily important. Production of antibodies that recognize background antigens is tolerated if it is within a range that does not interfere with production and collection of antibodies against the target antigen. Therefore, for example, even animals to be immunized in which immunotolerance has been induced against only the major background antigens may be utilized as favorable immunized animals of the present invention.

**[0026]** The present invention relates to methods for producing antibodies by utilizing nonhuman animals that carry genes encoding the abovementioned soluble forms of membrane proteins.

**[0027]** These methods comprise the step of immunizing nonhuman animals carrying a gene encoding the abovementioned soluble form of a membrane protein with an immunogen comprising, other than a target antigen, this membrane protein as a background antigen, and the step of obtaining antibodies against the previously-described target antigen or genes encoding these antibodies.

**[0028]** The immunogens of the present invention comprise, other than a target antigen, at least a membrane protein as a background antigen. Generally, a target antigen comprises substances derived from biological materials. Biological materials are complex mixtures comprising various components. Thus, target antigens are usually prepared using various mixtures as starting materials. Therefore, it is difficult to obtain highly-purified target antigens. In other words, it involves a lot of time and effort to isolate a large quantity of a highly pure target antigen. The present invention provides methods that enable efficient acquisition of antibodies against target antigens using such immunogens which have, other than a target antigen, membrane proteins contaminating as background antigens.

**[0029]** More specifically, examples of the immunogens of the present invention comprise cells, cell culture solutions, cell lysates, viruses, and crude antigens, in which membrane proteins may be contaminating as background antigens. When using cells or viruses, a gene encoding a desired antigen can be introduced into the cells or viruses by gene recombination techniques, and those that artificially express the desired antigen can be used. Whole cells or viruses as well as portions thereof can be used as the immunogens. Furthermore, just cell membrane or viral envelope portions may be used as the immunogens. When such whole cells or viruses, or portions thereof, such as their cell membrane or viral envelope, are used as the immunogen, membrane proteins comprised in the cell membrane or viral envelope contaminate as background antigens.

**[0030]** One preferable immunogen of the present invention is a viral particle or portion thereof. Viruses are comprised of relatively simple components, including nucleic acids, and limited proteins, saccharides, and such. Consequently, the types of background antigens that may interfere with target antigen acquisition are also limited. Background antigens from viral particles or portions thereof that interfere with the acquisition of target antigen comprise membrane proteins on the surface of the particles. When administered to the animals to be immunized, the particle surfaces are highly antigenic, and can readily induce antibody production. Therefore, the methods for producing antibodies based on the present invention can be carried out more favorably if, even from among these few background antigens, immunotolerance in the animals to be immunized is induced against background antigens that are membrane proteins on the particle surface and the like.

**[0031]** In the present invention, baculovirus is one among the preferred among the viruses that can be used as immunogens. Baculoviruses are insect viruses that comprise a structure whereby a double-stranded DNA genome is covered with a capsid protein. Expression systems using Nucleopolyhedrovirus (NPV), a type of baculovirus, are useful as systems for expressing exogenous genes. NPV comprises strong promoter activity. Therefore, any protein can be produced in large quantities by inserting an exogenous gene into the NPV genome. Specifically, strong expression of any exogenous gene is induced by recombinantly substituting the gene coding for the protein called polyhedron with the exogenous gene.

**[0032]** The foreign genes that are expressed in the aforementioned baculovirus expression systems are not particularly limited, and any gene may be used; however, since baculoviruses can be utilized as systems suitable for expressing membrane proteins, an example of a suitable gene is a gene encoding a membrane protein. In the baculovirus expression systems, a subject membrane protein can be expressed along with a baculovirus envelope protein in a form that retains its structure. Another advantage of the baculovirus expression systems is that the expression products can be easily recovered as budding viral particles.

**[0033]** As methods for expressing membrane proteins which are the target antigens using baculoviruses, for example, the method using budding baculoviruses described in WO 98/46777 and Loisel *et al.* (Loisel, T.P. et al., Nature Biotech. 15: 1300-1304 (1997)) can be used. More specifically, a recombinant vector for insect cells comprising a gene encoding an exogenous protein is constructed, and introduced, along with baculoviral DNA, into insect cells such as Sf9. The exogenous membrane protein encoded by the recombinant vector is expressed on mature viral particles (virions), which are released by infected cells to the outside of cells prior to infected cell death. Recombinant viruses that express the exogenous protein can thus be obtained.

**[0034]** In the present invention, a budding virus is a virus that is released from infected cells by budding. Generally, viruses covered with an envelope can bud from cells infected with these viruses, and are released continuously, even when the cells have not been destroyed. On the other hand, adenoviruses that are not covered by an envelope, and herpes viruses that are covered by a nuclear envelope, are released from the cells all at once, upon cell destruction. Budding viruses are particularly preferable in the present invention. In addition, those skilled in the art can suitably select hosts to be infected with a recombinant virus, depending on the type of virus used, so long as viral replication is possible in the host. For example, insect cells such as Sf9 cells can be used when using baculoviruses. Generally, protein expression systems using baculoviruses and insect cells are considered to be useful systems because modifications that occur at the same time as translation or post-translationally, such as fatty acid acetylation or glycosylation, are carried out in the same way as with mammalian cells and because the expression level of heterologous proteins in such systems is greater than that in mammalian cell systems (Luckow V.A. and Summers M.D., *Viol.* 167: 56 (1988)).

**[0035]** The viruses expressing exogenous proteins, which are the target antigens, can be obtained by, for example, culturing a host that has been infected with a recombinant virus comprising a gene that encodes an exogenous protein. Alternatively, using methods such as the above-mentioned methods of W0 98/46777 and *Loisel et al.* (Loisel, T.P. et al., *Nature Biotech.* 15: 1300-1304 (1997)), a recombinant vector encoding an exogenous protein can be introduced into an insect cell along with a baculovirus, and exogenous proteins can be expressed on the envelope of the baculovirus released outside of the cell. In addition, using methods like that of *Strehlow et al.* (D. Strehlow et al., *Proc. Natl. Acad. Sci. USA.* 97: 4209-4214 (2000)), packaging cells such as PA317 can be infected with recombinant Moloney murine leukemia viruses, which are constructed using vectors derived from Moloney viruses into which exogenous protein-encoding genes have been introduced, and the exogenous proteins can be expressed on the envelope of viruses released outside of the cells. These are examples of viruses for expressing exogenous proteins and the viruses of the present invention that express exogenous proteins, useful as immunogens, are not limited to those that are constructed using the above methods.

**[0036]** Recombinant viruses constructed as described above can be purified using known methods, as necessary. For example, known methods for purifying viruses comprise augmented density gradient centrifugation (Albrechtsen et al., *J. Virological Methods* 28: 245-256 (1990); Hewish et al., *J. Virological Methods* 7: 223-228 (1983)), size exclusion chromatography (Hjorth and Mereno-Lopez, *J. Virological Methods* 5: 151-158 (1982); Crooks et al., *J. Chrom.* 502: 59-68 (1990); Mento S.J. (Viagene, Inc.) 1994 Williamsburg Bioprocessing Conference), affinity chromatography using monoclonal antibodies, sulphated fucose-containing polysaccharides and the like (Najayou et al., *J. Virological Methods* 32: 67-77 (1991); Diaco et al., *J. Gen. Virol.* 67: 345-351 (1986); Fowler, *J. Virological Methods* 11: 59-74 (1986); Japanese Patent Saikohyo Publication No. (JP-A) 97/032010 (unexamined Japanese national phase publication corresponding to a Japanese international publication)), and DEAE ion exchange chromatography (Haruna et al., *Virology* 13: 264-267 (1961)). Thus, purification can be carried out using the above methods or combinations thereof.

**[0037]** Animals to be immunized are immunized using immunogens prepared as described above. The immunized animals used in the present invention are nonhuman animals in which immunotolerance against a background antigen membrane protein comprised in an immunogen has been induced. Induction of immunotolerance against a background antigen membrane protein can be carried out as described above, by making animals to be immunized carry a gene encoding a soluble form of this membrane protein.

**[0038]** When a baculovirus expression system, which was shown above as an expression system suitable for membrane protein preparation, is used for immunogen preparation, preferably, nonhuman animals made to carry a gene encoding a soluble gp64 and induced to have immunotolerance against gp64 are used as the immunized animals. Herein, nonhuman animals carrying a gene encoding the full-length gp64 may be used as the immunized animals, however, the use of soluble gp64 transgenic animals and such is preferred since they can be widely used, and can be produced efficiently since both males and females are fertile. Therefore, for example, in a preferred embodiment of the present invention, nonhuman animals carrying a gene encoding a soluble gp64 are used as immunized animals, and a budding baculovirus made to express a membrane protein as the target antigen is used as the immunogen to carry out the immunizations.

**[0039]** By using the antibody-production methods of the present invention, the inhibitory effect on the acquisition of antibodies against a target antigen due to contamination of membrane proteins as background antigens can be suppressed. Consequently, the use of this invention enables sufficient application of the advantages of a baculovirus expression system as an exogenous protein expression system, even in the preparation of immunogens.

**[0040]** Well-known methods can be used for the methods of immunizing to obtain antibodies. Animals can be immunized with an immunogen using known methods. General methods comprise injecting a sensitizing antigen into a mammal by subcutaneous or intraperitoneal injection. Specifically, an immunogen is diluted with an appropriate volume of Phosphate-Buffered Saline (PBS), physiological saline, or such and as desired, the suspension is mixed with an appropriate volume of a conventional adjuvant. This is emulsified and administered to the mammals. For example, Freund's complete adjuvant can be used as an adjuvant. In addition, after this, an immunogen that has been mixed with an appropriate volume of Freund's incomplete adjuvant is preferably administered several times every four to 21 days. In this way

immunization occurs, and the increased level of a desired antibody in the serum can be confirmed using conventional methods.

**[0041]** An increase in the level of a desired antibody in the serum is confirmed, blood is collected from the immunized mammals, and the serum is separated. As polyclonal antibodies, serum comprising polyclonal antibodies can be used. Where necessary, fractions comprising polyclonal antibodies can be isolated from this serum, and this fraction can also be used.

**[0042]** Methods for producing monoclonal antibodies can be combined with the antibody production methods of the present invention. After confirming the increase in the level of the intended antibody in the serum of a mammal that was sensitized by the above-described antigen, the antibody-producing cells are extracted from the mammal and cloned to obtain monoclonal antibodies. Spleen cells and such can be used as antibody-producing cells. Antibody-producing cells can be cloned by cell fusion methods. Mammalian myeloma cells and such can be used as parent cells to be fused with the above-mentioned antibody-producing cells. Even more preferably, myeloma cells that comprise unique auxotrophy or drug resistance can be examples of useful selective markers for fusion cells (hybridoma cells). By basically following the methods known in the art, fusion cells can be obtained from the antibody-producing cells and the myeloma cells described above. Methods for producing monoclonal antibodies by using the cell fusion techniques have been established, for example, by Milstein *et al.* (Galfre, G. and Milstein, C., *Methods Enzymol.* (1981) 73, 3-46).

**[0043]** The hybridoma cells produced by cell fusion techniques are selected by culturing in a selective medium. A selective medium is chosen in accordance with the characteristic features and such of the myeloma cells used for the cell fusion. HAT medium (a medium comprising hypoxanthine, aminopterin, and thymidine), for example, can be used as a selective medium. The hybridoma cells are cultured in the HAT medium for a time sufficient to kill all cells other than the intended hybridoma cells (e.g. all non-fused cells). Generally, hybridoma cells can be selected by continuing culture for several days to several weeks. Then, a standard limiting dilution method is carried out to screen and clone the hybridoma cells that produce the subject antibodies.

**[0044]** Subsequently, the hybridoma cells thus obtained can be intraperitoneally transplanted into mice to obtain ascites fluid comprising the monoclonal antibodies. Monoclonal antibodies can also be purified from the ascites fluid. For example, monoclonal antibodies can be purified by ammonium sulfate precipitation methods, protein A or protein G columns, DEAE ion exchange chromatography, or affinity columns coupled with a target antigen.

**[0045]** Monoclonal antibodies obtained in this way can also be made into recombinant antibodies produced using gene recombination technologies (for example, see Borrebaeck, C.A.K. and Larrick, J.W., *Therapeutic Monoclonal Antibodies*, UK, Macmillan Publishers Ltd., 1990). Recombinant antibodies are produced by cloning the DNAs that encode them from antibody-producing cells, such as hybridomas and antibody-producing sensitized lymphocytes, then incorporating these DNAs into a suitable vector, and introducing this vector into a host.

**[0046]** Furthermore, antibody fragments and modified antibodies can be obtained by combining antibody alteration and modification techniques with the antibody production method of the present invention. For example, an antibody fragment can be an Fab, F(ab')<sub>2</sub>, Fv, or a single chain Fv (scFv) where the Fvs of an H chain and L chain are linked by a suitable linker (Huston, J.S. *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, (1988) 85, 5879-5883). Antibodies bound to various molecules such as polyethylene glycols (PEG), can also be used as the modified antibodies. Such modified antibodies can be obtained by chemically modifying the obtained antibodies. These methods have already been established in the art.

**[0047]** The methods for producing antibodies of the present invention can be combined with modification techniques used for human antibodies. Human antibodies of interest can be obtained by using transgenic animals carrying the complete repertoire of human antibody genes as a basis (see International Patent Application Publication Nos. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735), introducing a gene encoding a soluble form of a background antigen, making them carry the ability to produce human antibodies and the immunotolerance against the background antigen, and immunizing them with a desired antigen.

**[0048]** The antibodies obtained by the methods of the present invention can be chimeric antibodies comprising non-human antibody-derived variable regions, derived from the immunized animals, and human antibody-derived constant regions. In addition, they can also be humanized antibodies comprising complementarity determining regions (CDRs) of non-human antibodies derived from the immunized animals and the framework regions (FRs) and constant regions derived from human antibodies. These modified antibodies can be produced using known methods. Specifically, for example, a chimeric antibody is an antibody comprising the antibody heavy chain and light chain variable regions of an immunized animal, and the antibody heavy chain and light chain constant regions of a human. A chimeric antibody can be obtained by (1) ligating a DNA encoding a variable region of an immunized animal-derived antibody to a DNA encoding a constant region of a human antibody; (2) incorporating this into an expression vector; and (3) introducing the vector into a host for production of the antibody.

**[0049]** A humanized antibody, which is also called a reshaped human antibody, is a modified antibody. A humanized antibody is constructed by transplanting a complementarity determining region (CDR) of an antibody derived from an immunized animal, into the CDR of a human antibody. Conventional genetic recombination techniques for the preparation of such antibodies are known.



**[0050]** Specifically, a DNA sequence designed to ligate a mouse antibody CDR with a human antibody framework region (FR) is synthesized by PCR, using several oligonucleotides constructed to comprise overlapping portions at their ends. A humanized antibody can be obtained by (1) ligating the resulting DNA to a DNA which encodes a human antibody constant region; (2) incorporating this into an expression vector; and (3) introducing the vector into a host to produce the antibody (see, European Patent Application Publication No. EP 239,400, and International Patent Application Publication No. WO 96/02576). Those human antibody FRs that are ligated via the CDR, such that the CDR forms a favorable antigen-binding site, are selected. As necessary, amino acids in the framework region of an antibody variable region may be substituted such that the CDR of a reshaped human antibody forms an appropriate antigen-binding site (Sato, K. et al., Cancer Res. (1993) 53, 851-856).

**[0051]** Furthermore, genes coding for the antibodies can be obtained from the antibody-producing cells of an immunized animal. Methods used to obtain genes that code for antibodies are not limited. For example, genes coding for antibodies can be obtained by amplification using the PCR method, by using as templates those genes that code for variable regions or CDRs. Primers for the amplification of genes that code for antibodies are known in the art. Subject antibodies can be produced by expressing genes thus obtained in an appropriate expression system. Alternatively, the genes obtained by the present invention can be utilized to produce various modified antibodies (chimeric antibodies comprising human antibody-derived constant regions and humanized antibodies in which the CDRs of an immunized animal-derived antibody is transplanted to the CDRs of a human antibody).

**[0052]** The present invention provides systems for antibody production that comprise nonhuman animals carrying a gene encoding a soluble form of a membrane protein.

**[0053]** When an immunogen is prepared using a viral expression vector, in certain cases, membrane proteins derived from that virus or from host cells into which the viral expression vector has been introduced may contaminate as background antigens. These background antigen membrane proteins are not products of the exogenous target antigen gene, and in most cases, they are derived from the expression system, such as from the vector or host. Therefore, the background antigen membrane proteins that may contaminate are identified for every expression system. Then, a gene encoding a soluble form of this membrane protein is introduced into nonhuman animals by transgenic techniques, and whether immunotolerance against the membrane protein has been induced is confirmed in the obtained transgenic animals. Whether or not immunotolerance has been induced in the nonhuman animals can be confirmed as indicated in the Examples, by confirming the production of antibodies against the background antigen membrane protein in the serum.

**[0054]** Because the background antigen membrane protein is expressed in its soluble form, the expression of unfavorable phenotypes, such as the loss of fertility in males observed with the baculovirus gp64, is avoided in these nonhuman animals in which the induction of immunotolerance against the background antigen has been confirmed; such animals may thus be provided as widely useful animals to be immunized. Therefore, systems that can support efficient antibody production can be constructed by combining the animals to be immunized that carry a gene encoding a soluble form of a membrane protein of the present invention with an expression system that produces this membrane protein as a background antigen.

**[0055]** For example, by combining a baculovirus expression system described in detail above with nonhuman animals carrying a gene encoding a soluble gp64, the advantages of a baculovirus expression system can be reflected in antibody production. More specifically, in a baculovirus expression system, desired proteins, particularly membrane proteins, can be expressed as target antigens along with gp64 while maintaining their three-dimensional structure, and the expression products can be easily collected as budding viruses. These budding viruses are used as the immunogens and immunization is performed on the nonhuman animals carrying a gene encoding a soluble gp64 as the immunized animals. Since immunotolerance against gp64 is induced in these nonhuman animals carrying a gene encoding a soluble gp64, even if a large amount of gp64 is expressed on the budding virus serving as the immunogen, antibody production against this gp64 is suppressed and antibodies against the membrane protein serving as the target antigen can be produced. Therefore, even when gp64 is present on a baculovirus as a background antigen, by using nonhuman animals carrying a gene encoding a soluble gp64, antibody production against the target antigen can be favorably induced. As a result, the antibodies obtainable by the present system will be extremely pure antibodies against the target antigen.

**[0056]** All prior art references cited herein are incorporated by reference into this description.

## Examples

### [Example 1] Construction of an sgp64 transgenic vector

**[0057]** The transmembrane region (nucleotides 1465 to 1539) was deleted from the gp64 gene (SEQ ID NO: 1; full length: 1539 bp) to prepare by PCR a gene fragment comprising only the extracellular region (soluble gp64; 1464 bp; SEQ ID NO: 3).

**[0058]** More specifically, a 5' primer in which the 5'-terminal sequence of gp64, the restriction enzyme EcoRI recognition

sequence, and a KOZAK sequence are linked (64F1: 5'-GAATTCCACCATGGTAAGCGCTATTGTT-3'; SEQ ID NO: 5); a 3' primer in which the EcoRI recognition sequence is 5'-end linked to the sequence immediately before the transmembrane region of gp64 (s64R1:

5'-GAATTCTCATTATACATGACCAAACATGAACGA-3'; SEQ ID NO: 6) (Fig. 1-a and Fig. 1-b); and the pCAG-gp64 vector serving as a template DNA were used, and a polymerase chain reaction (PCR) was performed under the following conditions: the composition of the PCR reaction solution was 5  $\mu$ L of 10x ExTaq buffer (TaKaRa), 4  $\mu$ L of dNTP mixture comprised in the ExTaq kit, 1  $\mu$ L of 64F1 primer (10  $\mu$ mole/L), 1  $\mu$ L of s64R1 primer (10  $\mu$ mole/L), 1  $\mu$ L of pCAG-gp64 (500 pg/ $\mu$ L), 0.5  $\mu$ L of ExTaq (5 units/ $\mu$ L, TaKaRa), and 37.5  $\mu$ L of H<sub>2</sub>O. The reaction was carried out by heating at 94 °C for five minutes, and then performing 25 cycles of 94 °C for 15 seconds, 57 °C for 30 seconds, and 72 °C for 30 seconds. The mixture was then treated at 72 °C for seven minutes, and stored at 4 °C. The amplified band was subcloned into pGEM-Teasy (Promega) and *E. coli* (DH5 $\alpha$ , TOYOBO) were transformed with this. Colony PCR was performed using the T7 primer (5'-TAATACGACTCACTATA-3', SEQ ID NO: 7) and SP6 primer (5'-CATACGATTTAGGTGACAC-TATAG-3', SEQ ID NO: 8), the nucleotide sequences of clones found to carry the insert were analyzed with an ABI Prism 377 DNA sequencer using the BigDye Cycle Sequence kit (Applied Biosystems) and the T7 primer or the SP6 primer, and a clone carrying the desired gene was confirmed. The fragment comprising gp64 was cut out from this clone by EcoRI restriction enzyme treatment, inserted into pCAGGS vector treated with the restriction enzyme EcoRI, and *E. coli* (DH5 $\alpha$ ) were transformed with this. The direction of insertion of the gp64 fragment was determined from the size of the band (approximately 2.1 kb) obtained by XhoI and XbaI restriction enzyme treatment and the pCAG-sgp64 vector was produced (Fig. 2). The clone as designed was cultured overnight at 37 °C using 250 mL of LB medium and purified using Endofree MAXI kit (QIAGEN) to obtain the plasmid (581.6 of  $\mu$ g).

#### [Example 2] Establishment of sgp64Tgm

**[0059]** A DNA injection fragment for use in Tgm production was prepared by treating the pCAG-sgp64 vector with the restriction enzymes Sall and PstI, then cutting out the fragment comprising the sgp64 gene (approximately 3.7 kb), collecting the fragment using a Gel Extraction Kit (QIAGEN), and then diluting this fragment to 3 ng/ $\mu$ L using PBS<sup>-</sup>. Mouse pronuclear stage embryos into which the DNA fragment was to be inserted were collected as follows: BALB/cA female mice (Japan Clea) were subjected to superovulation treatment (5 IU of eCG (Serotropin, Teikoku Zoki) was administered intraperitoneally, and 48 hours later, 5 IU of hCG (Puberogen, Sankyo) was administered intraperitoneally), and then mated with male mice of the same strain (Japan Clea). The next morning, the oviducts of female mice found to have a vaginal plug were perfused to collect the pronuclear stage embryos. The DNA fragment was injected into pronuclear stage embryos using a micromanipulator ("Modern Techniques in Gene Targeting" (Yodosha), 190-207, 2000). The following day, embryos that had developed to the two-cell stage were transplanted into the left and right oviducts of one-day pseudopregnant recipient females at ten or so embryos per oviduct (20 or so embryos per individual). Recipient females that did not deliver litters by the expected delivery date were subjected to caesarian section and the pups were nursed by foster parents.

**[0060]** Based on the above methods, the DNA fragment was injected into 497 BALB/cA pronuclear stage mice embryos, and of these the 430 that developed into two-cell stage embryos were transplanted into the oviducts of pseudopregnant recipient females. As a result, 66 pups were obtained. Gene introduction into the obtained pups was confirmed as described below.

**[0061]** The mouse tails were collected and treated at 55 °C overnight with Lysis buffer (50 mM Tris-HCl pH8.0, 0.1 M NaCl, 20 mM EDTA, 1% SDS, Proteinase K 1 mg/mL; TaKaRa). Genomic DNA was then extracted using an automatic nucleic acid isolation system (KURABO, NA-1000P), and the introduced gene was confirmed by Southern blotting and PCR. Confirmation of the introduced gene by Southern blotting was performed by treating the extracted genomic DNA (15  $\mu$ g) with the restriction enzyme EcoRI, electrophoresing in an agarose gel, and transferring onto a nylon membrane (Hybond N+; Amersham) by the alkaline blotting method. An approximately 1.5 kb restriction enzyme EcoRI-treated fragment of the pCAG-sgp64 vector comprising sgp64 was used as a probe. This was labeled with <sup>32</sup>P and Southern blotting was performed by hybridizing it with the blotted genomic DNA. Hybridization was carried out overnight at 45 °C using 5x SSPE, 50% formamide, 5x Denhardt, and 0.5% SDS as the hybridization solution. The nylon membranes were washed in 2x SSC containing 0.1 % SDS at 65 °C for 30 minutes, and then in 1x SSC containing 0.1 % SDS at 65 °C for 30 minutes. Thereafter, signals were detected using BAS2000 (FUJIX).

**[0062]** Confirmation of the introduced gene by PCR was carried out using the above-mentioned 64F1 as the sense primer, and the above-mentioned s64R1 as the antisense primer, under the following conditions: the composition of the PCR reaction solution was 1  $\mu$ L of genomic DNA (100 ng/ $\mu$ L), 5  $\mu$ L of 10x ExTaq buffer (TaKaRa), 4  $\mu$ L of dNTP mixture comprised in the ExTaq kit, 1  $\mu$ L of 64F1 primer (10  $\mu$ mole/L), 1  $\mu$ L of s64R1 primer (10  $\mu$ mole/L), 0.5  $\mu$ L of ExTaq (5 units/ $\mu$ L, TaKaRa), and 37.5  $\mu$ L of H<sub>2</sub>O. The reaction was carried out by heating at 94 °C for five minutes, and then performing 35 cycles of 94 °C for 15 seconds, 57 °C for 30 seconds, and 72 °C for 30 seconds; subsequently, the mixture was treated at 72 °C for seven minutes, and then stored at 4 °C. The amplified product was subjected to electrophoresis,

## EP 1 731 032 A1

and the presence or absence of a band of approximately 1.5 kb was verified.

**[0063]** This method confirmed that three of the 66 pups were Tgm carrying the sgp64 gene (hereinafter, Tgm obtained by inserting the DNA fragment will be referred to as "founder mice") (Table 1). One of the three founder mice was male, and the other two were female.

Table 1

	Number of viable eggs/ number of eggs receiving injection	Number of eggs transplanted	Number of eggs implanted	Number of pups (female, male)	Number of weanlings (female, male)	Founder
1st	120/133	114	61	29 (15, 14)	28 (14, 14)	0
2nd	78/88	76	22	4 (2, 2)	4 (2, 2)	0
3rd	102/111	101	55	12 (7, 5)	11 (7, 4)	1 female, 1 male
4th	130/165	126	64	21 (11, 10)	15 (8, 7)	1 female
Total	430/497	417	202	66 (35, 31)	58 (31, 27)	2 females, 1 male

**[0064]** When eight weeks old, the obtained founder mice were mated with BALB/cA mice. Specifically, of the three founder mice, 26 pups were obtained by mating the male founder mouse (line number 41) with five females, and of these pups, 12 were Tgm (F1 mice). Nine of the 16 pups obtained from the first female founder mouse (line number 36) were Tgm (F1 mice, including males and females), and four of these were males (Table 2). Eight of the 15 pups obtained from the other female founder mouse (line number 51) were Tgm (F1 mice, including males and females), and one of these was a male (Table 2).

Table 2

Line number	Sex	Number of deliveries	Litter size	Number of Tgm (F1)
36	Female	2	7 females, 9 males	5 females, 4 males
41	Male	5	11 females, 15 males	4 females, 8 males
51	Female	2	8 females, 7 males	7 females, 1 male

[Example 3] Fertility of male Tgm

**[0065]** The fertility of the male Tgm (F1 mice) obtained in Example 2 was examined. Fertility was confirmed by mating eight-week-old male sgp64Tgm (F1 mice) with BALB/cA mice, and confirming the presence and number of pups.

**[0066]** Male Tgm (F1 mice) obtained from each of the three founder lines (one animal from each line) were mated with two females to give nine pups (five females, four males), nine pups (two females, seven males), and ten pups (six females, four males) respectively, and of these, nine pups (five females, four males), eight pups (two females, six males), and five pups (four females, one male) were Tgm (Table 3). The male Tgm in all three lines were confirmed to have normal fertility.

Fertility results of male sgp64Tgm (F1 mice)

Table 3

Line number	Number of deliveries	Litter size	Number of Tgm
36	2	5 females, 4 males	5 females, 4 males
41	2	2 females, 7 males	2 females, 6 males

(continued)

Line number	Number of deliveries	Litter size	Number of Tgm
51	2	6 females, 4 males	4 females, 1 male

[Example 4] Confirmation of tolerance to gp64 by Western blotting

**[0068]** To confirm induction of tolerance to gp64, sgp64Tgm were immunized with a budding baculovirus (pepT1-AcMNPV (pepT1-BV)), as set out below.

**[0069]** Immunization was carried out by producing an emulsion according to standard methods using Freund's complete adjuvant (Difco) and incomplete adjuvant (Difco), and administering it subcutaneously. The first immunizing dose was 1 mg/animal, and the second immunizing dose was 0.5 mg/animal. The second immunization was carried out 14 days after the first. After 17 days from the first immunization, blood was sampled from the orbit, and serum was collected. As controls, non-transgenic mice were immunized similarly, and their sera were collected.

**[0070]** The following Western blot analysis was carried out to confirm tolerance to gp64 in the Tgm:

pepT1-BV used as the antigen was subjected to SDS-PAGE at 1 µg/lane using a 12% gel and under reducing conditions. After electrophoresis, electroblotting onto a PVDF membrane was carried out. The serum collected above was diluted to 1/1000, and reacted with this membrane, which was then washed three times for five minutes at room temperature using PBS-T (PBS containing 0.05% Tween20). After washing, biotin-anti-mouse IgG(γ) (Zymed) diluted to 1/1000, and streptavidin-alkaline phosphatase (Zymed) were reacted with the membrane. Alkaline Phosphatase Staining Kit (Nakalai) was used for staining.

**[0071]** In the case of non-transgenic mice (non-Tgm), staining with anti-mouse IgG resulted in strong staining for all three mice (Fig. 3). On the other hand, there was hardly any gp64 staining for the sgp64Tgm, and this confirmed the induction of tolerance to gp64 in sgp64Tgm.

#### Industrial Applicability

**[0072]** The present invention provided new transgenic animals that overcome the problem of male infertility, which existed in conventional transgenic animals into which the gene for the baculovirus membrane protein gp64 had been introduced. The above-mentioned problem was solved by expressing a soluble gp64 (that is, expressing gp64 outside the cell membrane), which was prepared by methods such as deleting a sequence encoding the transmembrane region from the gene encoding the gp64 membrane protein. Therefore, the emergence of unfavorable phenotypes, such as the unfavorable characteristic of male infertility in transgenic animals into which a gene encoding a full-length membrane protein has been introduced, can be avoided in transgenic animals into which a gene encoding a soluble form of the membrane protein has been introduced, as in the present invention.

**[0073]** As described above, just as for transgenic animals into which genes encoding a full-length membrane protein had been introduced, transgenic animals into which genes encoding a soluble protein had been introduced have been confirmed to have induced immunotolerance to the membrane protein. Therefore, when the immunogens have contaminating membrane proteins as background antigens, it is advantageous to use, as animals to be immunized, the transgenic animals which carry genes encoding soluble proteins that lack a transmembrane region, and such, of these membrane proteins as exogenous genes. That is, since immunotolerance against background antigen membrane proteins is induced, antibodies specific to the desired antigen are produced advantageously, and since unfavorable phenotypes of transgenic animals into which the full-length membrane protein has been introduced can be avoided in these immunized animals, they will be utilized even more readily as systems for antibody production.

**[0074]** The antibodies produced using the animals of the present invention are not contaminated or very slightly contaminated by antibodies against background antigens, and they are therefore provided as highly pure antibodies.

## SEQUENCE LISTING

5 <110> CHUGAI SEIYAKU KABUSHIKI KAISHA

<120> Nonhuman animal for constructing antibody and method and system of constructing  
10 antibody using the same

<130> C1-A0326P

15 <150> JP2004-107669  
<151> 2004-03-31

20 <160> 10

<170> PatentIn version 3.1

25 <210> 1  
<211> 1539  
<212> DNA  
30 <213> Baculovirus

<220>  
<221> CDS  
35 <222> (1) .. (1539)  
<223>

40 <400> 1  
atg gta agc gct att gtt tta tat gtg ctt ttg gcg gcg gcg gcg cat 48  
Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His  
1 5 10 15

45 tct gcc ttt gcg gcg gag cac tgc aac gcg caa atg aag acg ggt ccg 96  
Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys Thr Gly Pro  
50 20 25 30

tac aag att aaa aac ttg gac att acc ccg ccc aag gaa acg ctg caa 144  
Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu Thr Leu Gln  
55

EP 1 731 032 A1

	35	40	45	
5	aag gac gtg gaa atc acc atc gtg gag acg gac tac aac gaa aac gtg			192
	Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn Glu Asn Val			
	50	55	60	
10	att atc ggc tac aag ggg tac tac cag gcg tat gcg tac aac ggc ggc			240
	Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr Asn Gly Gly			
	65	70	75	80
15	tcg ctg gat ccc aac aca cgc gtc gaa gaa acc atg aaa acg ctg aat			288
	Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys Thr Leu Asn			
20		85	90	95
	gtg ggc aaa gag gat ttg ctt atg tgg agc atc agg cag cag tgc gag			336
25	Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln Gln Cys Glu			
	100	105	110	
30	gtg ggc gaa gag ctg atc gac cgt tgg ggc agt gac agc gac gac tgt			384
	Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser Asp Asp Cys			
	115	120	125	
35	ttt cgc gac aac gag ggc cgc ggc cag tgg gtc aaa ggc aaa gag ttg			432
	Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly Lys Glu Leu			
	130	135	140	
40	gtg aag cgg cag aat aac aat cac ttt gcg cac cac acg tgc aac aaa			480
	Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr Cys Asn Lys			
	145	150	155	160
45	tcg tgg cga tgc ggc att tcc act tcg aaa atg tac agc agg ctc gag			528
	Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser Arg Leu Glu			
	165	170	175	
50	tgc cag gac gac acg gac gag tgc cag gta tac att ttg gac gct gag			576
	Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu Asp Ala Glu			
55	180	185	190	

EP 1 731 032 A1

5	ggc aac ccc atc aac gtg acc gtg gac act gtg ctt cat cga gac ggc Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His Arg Asp Gly	624
	195 200 205	
10	gtg agt atg att ctc aaa caa aag tct acg ttc acc acg cgc caa ata Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr Arg Gln Ile	672
	210 215 220	
15	aaa gct gcg tgt ctg ctc att aaa gat gac aaa aat aac ccc gag tcg Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn Pro Glu Ser	720
	225 230 235 240	
20	gtg aca cgc gaa cac tgt ttg att gac aat gat ata tat gat ctt tct Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr Asp Leu Ser	768
25	245 250 255	
30	aaa aac acg tgg aac tgc aag ttt aac aga tgc att aaa cgc aaa gtc Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys Arg Lys Val	816
	260 265 270	
35	gag cac cga gtc aag aag cgg ccg ccc act tgg cgc cac aac gtt aga Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His Asn Val Arg	864
	275 280 285	
40	gcc aag tac aca gag gga gac act gcc acc aaa ggc gac ctg atg cat Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp Leu Met His	912
	290 295 300	
45	att caa gag gag ctg atg tac gaa aac gat ttg ctg aaa atg aac att Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys Met Asn Ile	960
	305 310 315 320	
50	gag ctg atg cat gcg cac atc aac aag cta aac aat atg ctg cac gac Glu Leu Met His Ala His Ile Asn Lys Leu Asn Asn Met Leu His Asp	1008
55	325 330 335	

EP 1 731 032 A1

	ctg ata gtc tcc gtg gcc aag gtg gac gag cgt ttg att ggc aat ctc	1056
	Leu Ile Val Ser Val Ala Lys Val Asp Glu Arg Leu Ile Gly Asn Leu	
5	340 345 350	
	atg aac aac tct gtt tct tca aca ttt ttg tgc gac gac acg ttt ttg	1104
	Met Asn Asn Ser Val Ser Ser Thr Phe Leu Ser Asp Asp Thr Phe Leu	
10	355 360 365	
	ctg atg ccg tgc acc aat ccg ccg gca cac acc agt aat tgc tac aac	1152
	Leu Met Pro Cys Thr Asn Pro Pro Ala His Thr Ser Asn Cys Tyr Asn	
15	370 375 380	
	aac agc atc tac aaa gaa ggg cgt tgg gtg gcc aac acg gac tgc tgc	1200
	Asn Ser Ile Tyr Lys Glu Gly Arg Trp Val Ala Asn Thr Asp Ser Ser	
20	385 390 395 400	
	caa tgc ata gat ttt agc aac tac aag gaa cta gca att gac gac gac	1248
	Gln Cys Ile Asp Phe Ser Asn Tyr Lys Glu Leu Ala Ile Asp Asp Asp	
25	405 410 415	
	gtc gag ttt tgg atc ccg acc atc ggc aac acg acc tat cac gac agt	1296
	Val Glu Phe Trp Ile Pro Thr Ile Gly Asn Thr Thr Tyr His Asp Ser	
30	420 425 430	
	tgg aaa gat gcc agc ggc tgg tgc ttt att gcc caa caa aaa agc aac	1344
	Trp Lys Asp Ala Ser Gly Trp Ser Phe Ile Ala Gln Gln Lys Ser Asn	
35	435 440 445	
	ctc ata acc acc atg gag aac acc aag ttt ggc ggc gtc ggc acc agt	1392
	Leu Ile Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val Gly Thr Ser	
40	450 455 460	
	ctg agc gac atc act tcc atg gct gaa ggc gaa ttg gcc gct aaa ttg	1440
	Leu Ser Asp Ile Thr Ser Met Ala Glu Gly Glu Leu Ala Ala Lys Leu	
45	465 470 475 480	
	act tgc ttc atg ttt ggt cat gta gtt aac ttt gta att ata tta att	1488
50		
55		



EP 1 731 032 A1

Thr Ser Phe Met Phe Gly His Val Val Asn Phe Val Ile Ile Leu Ile  
485 490 495

gtg att tta ttt ttg tac tgt atg att aga aac cgt aat aga caa tat 1536  
Val Ile Leu Phe Leu Tyr Cys Met Ile Arg Asn Arg Asn Arg Gln Tyr

500 505 510

taa 1539

<210> 2

<211> 512

<212> PRT

<213> Baculovirus

<400> 2

Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His  
1 5 10 15

Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys Thr Gly Pro  
20 25 30

Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu Thr Leu Gln  
35 40 45

Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn Glu Asn Val  
50 55 60

Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr Asn Gly Gly  
65 70 75 80

Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys Thr Leu Asn  
85 90 95

Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln Gln Cys Glu  
100 105 110

EP 1 731 032 A1

Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser Asp Asp Cys  
115 120 125

5

Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly Lys Glu Leu  
130 135 140

10

Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr Cys Asn Lys  
145 150 155 160

15

Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser Arg Leu Glu  
165 170 175

20

Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu Asp Ala Glu  
180 185 190

25

Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His Arg Asp Gly  
195 200 205

30

Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr Arg Gln Ile  
210 215 220

35

Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn Pro Glu Ser  
225 230 235 240

40

Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr Asp Leu Ser  
245 250 255

45

Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys Arg Lys Val  
260 265 270

50

Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His Asn Val Arg  
275 280 285

55

Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp Leu Met His  
290 295 300

Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys Met Asn Ile

EP 1 731 032 A1

	305	310	315	320
5	Glu Leu Met His Ala His Ile Asn Lys Leu Asn Asn Met Leu His Asp			
		325	330	335
10	Leu Ile Val Ser Val Ala Lys Val Asp Glu Arg Leu Ile Gly Asn Leu			
		340	345	350
15	Met Asn Asn Ser Val Ser Ser Thr Phe Leu Ser Asp Asp Thr Phe Leu			
		355	360	365
20	Leu Met Pro Cys Thr Asn Pro Pro Ala His Thr Ser Asn Cys Tyr Asn			
		370	375	380
25	Asn Ser Ile Tyr Lys Glu Gly Arg Trp Val Ala Asn Thr Asp Ser Ser			
		385	390	395
				400
30	Gln Cys Ile Asp Phe Ser Asn Tyr Lys Glu Leu Ala Ile Asp Asp Asp			
		405	410	415
35	Val Glu Phe Trp Ile Pro Thr Ile Gly Asn Thr Thr Tyr His Asp Ser			
		420	425	430
40	Trp Lys Asp Ala Ser Gly Trp Ser Phe Ile Ala Gln Gln Lys Ser Asn			
		435	440	445
45	Leu Ile Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val Gly Thr Ser			
		450	455	460
50	Leu Ser Asp Ile Thr Ser Met Ala Glu Gly Glu Leu Ala Ala Lys Leu			
		465	470	475
				480
55	Thr Ser Phe Met Phe Gly His Val Val Asn Phe Val Ile Ile Leu Ile			
		485	490	495
	Val Ile Leu Phe Leu Tyr Cys Met Ile Arg Asn Arg Asn Arg Gln Tyr			
		500	505	510

5           <210> 3  
           <211> 1464  
           <212> DNA  
 10          <213> Baculovirus  
  
           <220>  
           <221> CDS  
 15          <222> (1).. (1464)  
           <223>  
  
 20          <400> 3  
           atg gta agc gct att gtt tta tat gtg ctt ttg gcg gcg gcg gcg cat           48  
           Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His  
           1                   5                   10                   15  
 25                   tct gcc ttt gcg gcg gag cac tgc aac gcg caa atg aag acg ggt ccg           96  
           Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys Thr Gly Pro  
                          20                   25                   30  
 30                   tac aag att aaa aac ttg gac att acc ccg ccc aag gaa acg ctg caa           144  
           Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu Thr Leu Gln  
                          35                   40                   45  
 35                   aag gac gtg gaa atc acc atc gtg gag acg gac tac aac gaa aac gtg           192  
           Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn Glu Asn Val  
                          50                   55                   60  
 40                   att atc ggc tac aag ggg tac tac cag gcg tat gcg tac aac ggc ggc           240  
           Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr Asn Gly Gly  
           65                   70                   75                   80  
 45                   tcg ctg gat ccc aac aca cgc gtc gaa gaa acc atg aaa acg ctg aat           288  
           Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys Thr Leu Asn  
                          85                   90                   95  
 50                     
 55

EP 1 731 032 A1

5	gtg ggc aaa gag gat ttg ctt atg tgg agc atc agg cag cag tgc gag Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln Gln Cys Glu 100 105 110	336
10	gtg ggc gaa gag ctg atc gac cgt tgg ggc agt gac agc gac gac tgt Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser Asp Asp Cys 115 120 125	384
15	ttt cgc gac aac gag ggc cgc ggc cag tgg gtc aaa ggc aaa gag ttg Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly Lys Glu Leu 130 135 140	432
20	gtg aag cgg cag aat aac aat cac ttt gcg cac cac acg tgc aac aaa Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr Cys Asn Lys 145 150 155 160	480
25	tcg tgg cga tgc ggc att tcc act tcg aaa atg tac agc agg ctc gag Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser Arg Leu Glu 165 170 175	528
30	tgc cag gac gac acg gac gag tgc cag gta tac att ttg gac gct gag Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu Asp Ala Glu 180 185 190	576
35	ggc aac ccc atc aac gtg acc gtg gac act gtg ctt cat cga gac ggc Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His Arg Asp Gly 195 200 205	624
40	gtg agt atg att ctc aaa caa aag tct acg ttc acc acg cgc caa ata Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr Arg Gln Ile 210 215 220	672
45	aaa gct gcg tgt ctg ctc att aaa gat gac aaa aat aac ccc gag tcg Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn Pro Glu Ser 225 230 235 240	720
50	gtg aca cgc gaa cac tgt ttg att gac aat gat ata tat gat ctt tct	768

EP 1 731 032 A1

	Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr Asp Leu Ser	
	245 250 255	
5		
	aaa aac acg tgg aac tgc aag ttt aac aga tgc att aaa cgc aaa gtc	816
	Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys Arg Lys Val	
10	260 265 270	
	gag cac cga gtc aag aag cgg ccg ccc act tgg cgc cac aac gtt aga	864
	Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His Asn Val Arg	
15	275 280 285	
	gcc aag tac aca gag gga gac act gcc acc aaa ggc gac ctg atg cat	912
20	Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp Leu Met His	
	290 295 300	
	att caa gag gag ctg atg tac gaa aac gat ttg ctg aaa atg aac att	960
25	Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys Met Asn Ile	
	305 310 315 320	
	gag ctg atg cat gcg cac atc aac aag cta aac aat atg ctg cac gac	1008
30	Glu Leu Met His Ala His Ile Asn Lys Leu Asn Asn Met Leu His Asp	
	325 330 335	
	ctg ata gtc tcc gtg gcc aag gtg gac gag cgt ttg att ggc aat ctc	1056
35	Leu Ile Val Ser Val Ala Lys Val Asp Glu Arg Leu Ile Gly Asn Leu	
	340 345 350	
40		
	atg aac aac tct gtt tct tca aca ttt ttg tgc gac gac acg ttt ttg	1104
	Met Asn Asn Ser Val Ser Ser Thr Phe Leu Ser Asp Asp Thr Phe Leu	
45	355 360 365	
	ctg atg ccg tgc acc aat ccg ccg gca cac acc agt aat tgc tac aac	1152
50	Leu Met Pro Cys Thr Asn Pro Pro Ala His Thr Ser Asn Cys Tyr Asn	
	370 375 380	
	aac agc atc tac aaa gaa ggg cgt tgg gtg gcc aac acg gac tgc tgc	1200
55	Asn Ser Ile Tyr Lys Glu Gly Arg Trp Val Ala Asn Thr Asp Ser Ser	

EP 1 731 032 A1

	385	390	395	400	
5	caa tgc ata gat ttt agc aac tac aag gaa cta gca att gac gac gac				1248
	Gln Cys Ile Asp Phe Ser Asn Tyr Lys Glu Leu Ala Ile Asp Asp Asp				
		405	410	415	
10	gtc gag ttt tgg atc ccg acc atc ggc aac acg acc tat cac gac agt				1296
	Val Glu Phe Trp Ile Pro Thr Ile Gly Asn Thr Thr Tyr His Asp Ser				
		420	425	430	
15	tgg aaa gat gcc agc ggc tgg tcg ttt att gcc caa caa aaa agc aac				1344
	Trp Lys Asp Ala Ser Gly Trp Ser Phe Ile Ala Gln Gln Lys Ser Asn				
20		435	440	445	
25	ctc ata acc acc atg gag aac acc aag ttt ggc ggc gtc ggc acc agt				1392
	Leu Ile Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val Gly Thr Ser				
		450	455	460	
30	ctg agc gac atc act tcc atg gct gaa ggc gaa ttg gcc gct aaa ttg				1440
	Leu Ser Asp Ile Thr Ser Met Ala Glu Gly Glu Leu Ala Ala Lys Leu				
		465	470	475	480
35	act tcg ttc atg ttt ggt cat gta				1464
	Thr Ser Phe Met Phe Gly His Val				
		485			
40					
	<210> 4				
	<211> 488				
45	<212> PRT				
	<213> Baculovirus				
50	<400> 4				
	Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His				
	1	5	10	15	
55	Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys Thr Gly Pro				

EP 1 731 032 A1

	20	25	30
5	Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu Thr Leu Gln		
	35	40	45
10	Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn Glu Asn Val		
	50	55	60
15	Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr Asn Gly Gly		
	65	70	75 80
20	Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys Thr Leu Asn		
	85	90	95
25	Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln Gln Cys Glu		
	100	105	110
30	Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser Asp Asp Cys		
	115	120	125
35	Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly Lys Glu Leu		
	130	135	140
40	Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr Cys Asn Lys		
	145	150	155 160
45	Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser Arg Leu Glu		
	165	170	175
50	Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu Asp Ala Glu		
	180	185	190
55	Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His Arg Asp Gly		
	195	200	205
60	Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr Arg Gln Ile		
	210	215	220



EP 1 731 032 A1

5	Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn Pro Glu Ser			
	225	230	235	240
10	Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr Asp Leu Ser			
		245	250	255
15	Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys Arg Lys Val			
		260	265	270
20	Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His Asn Val Arg			
		275	280	285
25	Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp Leu Met His			
		290	295	300
30	Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys Met Asn Ile			
	305	310	315	320
35	Glu Leu Met His Ala His Ile Asn Lys Leu Asn Asn Met Leu His Asp			
		325	330	335
40	Leu Ile Val Ser Val Ala Lys Val Asp Glu Arg Leu Ile Gly Asn Leu			
		340	345	350
45	Met Asn Asn Ser Val Ser Ser Thr Phe Leu Ser Asp Asp Thr Phe Leu			
		355	360	365
50	Leu Met Pro Cys Thr Asn Pro Pro Ala His Thr Ser Asn Cys Tyr Asn			
		370	375	380
55	Asn Ser Ile Tyr Lys Glu Gly Arg Trp Val Ala Asn Thr Asp Ser Ser			
	385	390	395	400
	Gln Cys Ile Asp Phe Ser Asn Tyr Lys Glu Leu Ala Ile Asp Asp Asp			
		405	410	415

# EP 1 731 032 A1

Val Glu Phe Trp Ile Pro Thr Ile Gly Asn Thr Thr Tyr His Asp Ser  
420 425 430

Trp Lys Asp Ala Ser Gly Trp Ser Phe Ile Ala Gln Gln Lys Ser Asn  
435 440 445

Leu Ile Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val Gly Thr Ser  
450 455 460

Leu Ser Asp Ile Thr Ser Met Ala Glu Gly Glu Leu Ala Ala Lys Leu  
465 470 475 480

Thr Ser Phe Met Phe Gly His Val  
485

<210> 5

<211> 28

<212> DNA

<213> Artificial

<220>

<223> an artificially synthesized primer sequence

<400> 5

gaattccacc atggttaagcg ctattgtt

<210> 6

<211> 33

<212> DNA

<213> Artificial

<220>

<223> an artificially synthesized primer sequence

<400> 6

gaattctcat tatacatgac caaacatgaa cga

33

5

<210> 7

<211> 17

10

<212> DNA

<213> Artificial

<220>

15

<223> an artificially synthesized primer sequence

<400> 7

20

taatacgact cactata

17

<210> 8

25

<211> 24

<212> DNA

<213> Artificial

30

<220>

<223> an artificially synthesized primer sequence

35

<400> 8

catacgattt aggtgacact atag

24

40

<210> 9

45

<211> 1486

<212> DNA

<213> Baculovirus

50

<220>

<221> CDS

55

<222> (2).. (1474)

&lt;400&gt; 9

5	g aat tcc acc atg gta agc gct att gtt tta tat gtg ctt ttg gcg gcg	49
	Asn Ser Thr Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala	
	1 5 10 15	
10	gcg gcg cat tct gcc ttt gcg gcg gag cac tgc aac gcg caa atg aag	97
	Ala Ala His Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys	
	20 25 30	
15	acg ggt ccg tac aag att aaa aac ttg gac att acc ccg ccc aag gaa	145
	Thr Gly Pro Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu	
20	35 40 45	
25	acg ctg caa aag gac gtg gaa atc acc atc gtg gag acg gac tac aac	193
	Thr Leu Gln Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn	
	50 55 60	
30	gaa aac gtg att atc ggc tac aag ggg tac tac cag gcg tat gcg tac	241
	Glu Asn Val Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr	
	65 70 75 80	
35	aac ggc ggc tgc ctg gat ccc aac aca cgc gtc gaa gaa acc atg aaa	289
	Asn Gly Gly Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys	
	85 90 95	
40	acg ctg aat gtg ggc aaa gag gat ttg ctt atg tgg agc atc agg cag	337
	Thr Leu Asn Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln	
	100 105 110	
45	cag tgc gag gtg ggc gaa gag ctg atc gac cgt tgg ggc agt gac agc	385
	Gln Cys Glu Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser	
	115 120 125	
50	gac gac tgt ttt cgc gac aac gag ggc cgc ggc cag tgg gtc aaa ggc	433
	Asp Asp Cys Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly	
55	130 135 140	

EP 1 731 032 A1

5	aaa gag ttg gtg aag cgg cag aat aac aat cac ttt gcg cac cac acg Lys Glu Leu Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr 145 150 155 160	481
10	tgc aac aaa tcg tgg cga tgc ggc att tcc act tcg aaa atg tac agc Cys Asn Lys Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser 165 170 175	529
15	agg ctc gag tgc cag gac gac acg gac gag tgc cag gta tac att ttg Arg Leu Glu Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu 180 185 190	577
20	gac gct gag ggc aac ccc atc aac gtg acc gtg gac act gtg ctt cat Asp Ala Glu Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His 195 200 205	625
25	cga gac ggc gtg agt atg att ctc aaa caa aag tct acg ttc acc acg Arg Asp Gly Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr 210 215 220	673
30	cgc caa ata aaa gct gcg tgt ctg ctc att aaa gat gac aaa aat aac Arg Gln Ile Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn 225 230 235 240	721
35	ccc gag tcg gtg aca cgc gaa cac tgt ttg att gac aat gat ata tat Pro Glu Ser Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr 245 250 255	769
40	gat ctt tct aaa aac acg tgg aac tgc aag ttt aac aga tgc att aaa Asp Leu Ser Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys 260 265 270	817
45	cgc aaa gtc gag cac cga gtc aag aag cgg ccg ccc act tgg cgc cac Arg Lys Val Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His 275 280 285	865
50		
55		

EP 1 731 032 A1

	aac gtt aga gcc aag tac aca gag gga gac act gcc acc aaa ggc gac	913
	Asn Val Arg Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp	
5	290 295 300	
	ctg atg cat att caa gag gag ctg atg tac gaa aac gat ttg ctg aaa	961
10	Leu Met His Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys	
	305 310 315 320	
	atg aac att gag ctg atg cat gcg cac atc aac aag cta aac aat atg	1009
15	Met Asn Ile Glu Leu Met His Ala His Ile Asn Lys Leu Asn Asn Met	
	325 330 335	
	ctg cac gac ctg ata gtc tcc gtg gcc aag gtg gac gag cgt ttg att	1057
20	Leu His Asp Leu Ile Val Ser Val Ala Lys Val Asp Glu Arg Leu Ile	
	340 345 350	
	ggc aat ctc atg aac aac tct gtt tct tca aca ttt ttg tcg gac gac	1105
25	Gly Asn Leu Met Asn Asn Ser Val Ser Ser Thr Phe Leu Ser Asp Asp	
	355 360 365	
30		
	acg ttt ttg ctg atg ccg tgc acc aat ccg ccg gca cac acc agt aat	1153
	Thr Phe Leu Leu Met Pro Cys Thr Asn Pro Pro Ala His Thr Ser Asn	
35	370 375 380	
	tgc tac aac aac agc atc tac aaa gaa ggg cgt tgg gtg gcc aac acg	1201
40	Cys Tyr Asn Asn Ser Ile Tyr Lys Glu Gly Arg Trp Val Ala Asn Thr	
	385 390 395 400	
	gac tcg tcg caa tgc ata gat ttt agc aac tac aag gaa cta gca att	1249
45	Asp Ser Ser Gln Cys Ile Asp Phe Ser Asn Tyr Lys Glu Leu Ala Ile	
	405 410 415	
	gac gac gac gtc gag ttt tgg atc ccg acc atc ggc aac acg acc tat	1297
50	Asp Asp Asp Val Glu Phe Trp Ile Pro Thr Ile Gly Asn Thr Thr Tyr	
	420 425 430	
55	cac gac agt tgg aaa gat gcc agc ggc tgg tcg ttt att gcc caa caa	1345

EP 1 731 032 A1

His Asp Ser Trp Lys Asp Ala Ser Gly Trp Ser Phe Ile Ala Gln Gln  
435 440 445

5

aaa agc aac ctc ata acc acc atg gag aac acc aag ttt ggc ggc gtc 1393  
Lys Ser Asn Leu Ile Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val

10

450 455 460

ggc acc agt ctg agc gac atc act tcc atg gct gaa ggc gaa ttg gcc 1441  
Gly Thr Ser Leu Ser Asp Ile Thr Ser Met Ala Glu Gly Glu Leu Ala

15

465 470 475 480

gct aaa ttg act tcg ttc atg ttt ggt cat gta taatgagaat tc 1486  
Ala Lys Leu Thr Ser Phe Met Phe Gly His Val

20

485 490

25

<210> 10

<211> 491

<212> PRT

30

<213> Baculovirus

<400> 10

35

Asn Ser Thr Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala  
1 5 10 15

40

Ala Ala His Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys  
20 25 30

45

Thr Gly Pro Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu  
35 40 45

50

Thr Leu Gln Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn  
50 55 60

55

EP 1 731 032 A1

5	Glu Asn Val Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr	65	70	75	80
10	Asn Gly Gly Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys	85	90	95	
15	Thr Leu Asn Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln	100	105	110	
20	Gln Cys Glu Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser	115	120	125	
25	Asp Asp Cys Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly	130	135	140	
30	Lys Glu Leu Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr	145	150	155	160
35	Cys Asn Lys Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser	165	170	175	
40	Arg Leu Glu Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu	180	185	190	
45	Asp Ala Glu Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His	195	200	205	
50					
55					



EP 1 731 032 A1

5 Arg Asp Gly Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr  
210 215 220

10 Arg Gln Ile Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn  
225 230 235 240

15 Pro Glu Ser Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr  
245 250 255

20 Asp Leu Ser Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys  
260 265 270

25 Arg Lys Val Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His  
275 280 285

30 Asn Val Arg Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp  
290 295 300

35 Leu Met His Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys  
305 310 315 320

40 Met Asn Ile Glu Leu Met His Ala His Ile Asn Lys Leu Asn Asn Met  
325 330 335

45 Leu His Asp Leu Ile Val Ser Val Ala Lys Val Asp Glu Arg Leu Ile  
340 345 350

55

EP 1 731 032 A1

Gly Asn Leu Met Asn Asn Ser Val Ser Ser Thr Phe Leu Ser Asp Asp  
355 360 365

5

Thr Phe Leu Leu Met Pro Cys Thr Asn Pro Pro Ala His Thr Ser Asn  
370 375 380

10

Cys Tyr Asn Asn Ser Ile Tyr Lys Glu Gly Arg Trp Val Ala Asn Thr  
385 390 395 400

15

Asp Ser Ser Gln Cys Ile Asp Phe Ser Asn Tyr Lys Glu Leu Ala Ile  
405 410 415

20

Asp Asp Asp Val Glu Phe Trp Ile Pro Thr Ile Gly Asn Thr Thr Tyr  
420 425 430

25

His Asp Ser Trp Lys Asp Ala Ser Gly Trp Ser Phe Ile Ala Gln Gln  
435 440 445

30

Lys Ser Asn Leu Ile Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val  
450 455 460

35

Gly Thr Ser Leu Ser Asp Ile Thr Ser Met Ala Glu Gly Glu Leu Ala  
465 470 475 480

40

Ala Lys Leu Thr Ser Phe Met Phe Gly His Val  
485 490

45

50

Claims

1. A nonhuman animal carrying a gene encoding a soluble form of a membrane protein.
- 5 2. The nonhuman animal of claim 1, which is a transgenic animal into which a gene encoding a soluble protein has been introduced exogenously.
3. The nonhuman animal of claim 2, which is a progeny of the transgenic animal into which a gene encoding a soluble protein has been introduced exogenously.
- 10 4. The nonhuman animal of any one of claims 1 to 3, wherein the membrane protein is derived from a virus.
5. The nonhuman animal of claim 4, wherein the virus is a baculovirus.
- 15 6. The nonhuman animal of claim 5, wherein the membrane protein is gp64.
7. The nonhuman animal of claim 6, wherein the soluble protein is gp64 that lacks a transmembrane region.
8. The nonhuman animal of claim 6, wherein the soluble protein comprises an extracellular region of gp64.
- 20 9. The nonhuman animal of any one of claims 1 to 8, wherein the nonhuman animal is a mouse.
10. The nonhuman animal of any one of claims 6 to 9, wherein the male is fertile.
- 25 11. A method for producing an antibody, which comprises the steps of:
  - immunizing the nonhuman animal of any one of claims 1 to 10 with an immunogen comprising a target antigen;  
and
  - 30 obtaining an antibody against the target antigen or a gene encoding such an antibody.
12. The method of claim 11 for producing an antibody, wherein the immunogen is a viral particle or a portion thereof.
13. The method of claim 12 for producing an antibody, wherein the virus is a baculovirus.
- 35 14. The method of any one of claims 11 to 13 for producing an antibody, wherein the target antigen is a membrane protein.
15. A system for producing an antibody, which comprises the nonhuman animal of any one of claims 1 to 10.

	10 64F1 20 30 40 50 60
p64	GAATTCCACC ATGGTAAGCG CTATTGTT TT ATATGTGCTT TTGGCGGCGG CGGCGCATTCTC N S T M V S A I V L Y V L L A A A A H S
	70 80 90 100 110 120
p64	TGCCTTTGCG GCGGAGCACT GCAACGCGCA AATGAAGACG GGTCCGTACA AGATTAAAAA A F A A E H C N A Q M K T G P Y K I R N
	130 140 150 160 170 180
p64	CTTGGACATT ACCCCGCCCA AGGAAACGCT GCAAAAGGAC GTGGAAATCA CCATCGTGGA L D I T P P K E T L Q K D V E I T I V E
	190 200 210 220 230 240
p64	GACGGACTAC AACGAAAACG TGATTATCGG CTACAAGGGG TACTACCAGG CGTATGCGTA T D Y N E N V I I G Y K G Y Y Q A Y A Y
	250 260 270 280 290 300
p64	CAACGGCGGC TCGCTGGATC CCAACACACG CGTCGAAGAA ACCATGAAAA CGCTGAATGT N G G S L D P N T R V E E T M K T L N V
	310 320 330 340 350 360
p64	GGGCAAAGAG GATTGCTTA TGTGGAGCAT CAGGCAGCAG TCGGAGGTGG GCGAAGAGCT G K E D L L M W S I R O Q C E V G E E L
	370 380 390 400 410 420
p64	GATCGACCGT TGGGGCAGTG ACAGCGACGA CTGTTTTTCG GACAACGAGG GCCGCGGCCA I D R W G S D S D D C F R D N E G R G Q
	430 440 450 460 470 480
p64	GTGGGTCAAA GGCAAGAGT TGGTGAAGCG GCAGAATAAC AATCACTTTG CGCACCACAC W V K G K E L V K R Q N N N H F A H H T
	490 500 510 520 530 540
p64	GTGCAACAAA TCGTGGCGAT GCGGCATTTC CACTTCGAAA ATGTACAGCA GGCTCGAGTG C N K S W R C G I S T S K M Y S R L E C
	550 560 570 580 590 600
p64	CCAGGACGAC ACGGACGAGT GCCAGGTATA CATTTTGGAC GCTGAGGGCA ACCCCATCAA Q D D T D E C Q V Y I L D A E G N P I N
	610 620 630 640 650 660
p64	CGTGACCGTG GACACTGTGC TTCATCGAGA CGGCGTGAGT ATGATTCTCA AACAAAAGTC V T V D T V L H R D G V S M I L K Q K S
	670 680 690 700 710 720
p64	TACGTTTACC ACGCGCCAAA TAAAAGCTGC GTGTCTGCTC ATTAAAGATG ACAAAAATAA T F T T R Q I K A A C L L I K D D K N N

FIG. 1-a

	730	740	750	760	770	780
p64	CCCCGAGTCG	GTGACACGCG	AACACTGTTT	GATTGACAAT	GATATATATG	ATCTTTCTAA
	P E S V T R	E H C L	I D N	D I Y	D L S	K
	790	800	810	820	830	840
p64	AAACACGTGG	AACTGCAAGT	TTAACAGATG	CATTAAACGC	AAAGTCGAGC	ACCGAGTCAA
	N T W N C K	F N R C	I K R	K V E	H R V	K
	850	860	870	880	890	900
p64	GAAGCGGCCG	CCCACTTGGC	GCCACAACGT	TAGAGCCAAG	TACACAGAGG	GAGACACTGC
	K R P P T W	R H N V	R A K	Y T E	G D T	A
	910	920	930	940	950	960
p64	CACCAAAGGC	GACCTGATGC	ATATTCAAGA	GGAGCTGATG	TACGAAAACG	ATTTGCTGAA
	T K G D L M	H I Q E	E L M	Y E N	D L L	K
	970	980	990	1000	1010	1020
p64	AATGAACATT	GAGCTGATGC	ATGCGCACAT	CAACAAGCTA	AACAATATGC	TGCACGACCT
	M N I E L M	H A H I	N K L	N N M	L H D	L
	1030	1040	1050	1060	1070	1080
p64	GATAGTCTCC	GTGGCCAAGG	TGGACGAGCG	TTTGATTGGC	AATCTCATGA	ACAACTCTGT
	I V S V A K	V D E R	L I G	N L M	N N S	V
	1090	1100	1110	1120	1130	1140
p64	TTCTTCAACA	TTTTTGTCGG	ACGACACGTT	TTTGCTGATG	CCGTGCACCA	ATCCGCCGGC
	S S T F L S	D D T F	L L M	P C T	N P P	A
	1150	1160	1170	1180	1190	1200
p64	ACACACCAGT	AATTGCTACA	ACAACAGCAT	CTACAAAGAA	GGGCGTTGGG	TGGCCAACAC
	H T S N C Y	N N S I	Y K E	G R W	V A N	T
	1210	1220	1230	1240	1250	1260
p64	GGACTCGTCG	CAATGCATAG	ATTTTAGCAA	CTACAAGGAA	CTAGCAATTG	ACGACGACGT
	D S S Q C I	D F S N	Y K E	L A I	D D D	V
	1270	1280	1290	1300	1310	1320
p64	CGAGTTTTTG	ATCCCGACCA	TCGGCAACAC	GACCTATCAC	GACAGTTGGA	AAGATGCCAG
	E F W I P T	I G N T	T Y H	D S W	K D A	S
	1330	1340	1350	1360	1370	1380
p64	CGGCTGGTCG	TTTATTGCCC	AACAAAAAAG	CAACCTCATA	ACCACCATGG	AGAACACCAA
	G W S F I A	Q Q K S	N L I	T T M	E N T	K
	1390	1400	1410	1420	1430	1440
p64	GTTTGGCGGC	GTCGGCACCA	GTCTGAGCGA	CATCACTTCC	ATGGCTGAAG	GCGAATTGGC
	F G G V G T	S L S D	I T S	M A E	G E L	A
	1450	1460	1470	1480	1490	1500
p64	CGCTAAATTG	ACTTCGTTCA	TGTTTGGTCA	TGTATAATGA	GAATTC	(SEQ ID NO:9)
	A K L T S F	M F G H	V * *	E F	(SEQ ID NO:10)	

FIG. 1-b




FIG. 2




FIG. 3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006298

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl. <sup>7</sup> A01K67/027, C07K16/18, C12N15/09  According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl. <sup>7</sup> A01K67/027, C07K16/18, C12N15/09  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) BIOTECHNOLOGY ABSTRACT (DIALOG), BIOSIS (DIALOG), MEDLINE (STN), WPI (DIALOG), JSTPlus (JOIS), SwissProt/PIR/GeneSeq, GenBank/EMBL/DDBJ/GeneSeq		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X/A	TAMURA Y., et al., CD14 transgenic mice expressing membrane and soluble forms: comparisons of levels of cytokines and lethalities in response to lipopolysaccharide between transgenic and non-transgenic mice., Int.Immunol., (1999), Vol.11, No.3, p.333-9.	1-3,9-10/ 4-8,11-15
X/A	WATANABE, C. et al., Enhanced immune responses in transgenic mice expressing a truncated form of the lymphocyte semaphoring CD100, J.Immunol., (2001), Vol.167, No.8, p.4321-8.	1-2,9/ 3-8,10-15
Y	LU, W., et al., Characterization of a truncated soluble form of the abculovirus (AcMNPV) major envelope protein Gp64, Protein Expr.Purif., (2002), Vol.24, No.2, pages 196 to 201	1-15
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 23 June, 2005 (23.06.05)		Date of mailing of the international search report 12 July, 2005 (12.07.05)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006298

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HEFFERON, K.L., et al., Host cell receptor binding by baculovirus GP64 and kinetics of virion entry, Virology (1999), Vol.258, No.2, p.455-68	1-15
Y	Toshihiko OTOMO et al., "Gp64 Hatsugen/CCR2 Knockout Mouse Narabini COR2 Hatsugen Baculovirus o Mochiita Kinoteki Kotai no Sakusei", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu, (2003), Vol.26, page 660	1-15
Y	Norio KAMATA et al., "gp64 Hatsugen Mouse no Sakushutsu Narabini Hatsugagata Baculovirus ni Taisuru Tolerance Yudo", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu (2003), Vol.26, page659	1-15
Y	WO 2003/104453 A1 (Chugai Pharmaceutical Co., Ltd.), 18 December, 2003 (18.12.03), Full text & AU 2003242024 A1 & EP 1514928 A1	1-15

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006298

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

The matter common to claims 1 to 15 resides in a nonhuman animal carrying a gene encoding a soluble protein of a membrane protein.

However, a transgenic mouse carrying a gene encoding a soluble protein of a membrane protein was known in public on the priority date of the present case (see, Int.Immunol (1999), Vol.11, No.3, p.333-9, J.Immunol (2001), Vol.167, No.8, p.4321-8, etc.). Thus, this technical feature does not make a contribution over prior art, considering the disclosures in the above documents, and, therefore cannot be considered as a special technical feature. Furthermore, there is no the same or corresponding special technical feature.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 03104453 A [0004]
- WO 9846777 A [0033] [0035]
- JP 9032010 A [0036]
- WO 9312227 A [0047]
- WO 9203918 A [0047]
- WO 9402602 A [0047]
- WO 9425585 A [0047]
- WO 9634096 A [0047]
- WO 9633735 A [0047]
- EP 239400 A [0050]
- WO 9602576 A [0050]

## Non-patent literature cited in the description

- *Biotechnology*, 1995, vol. 13, 1079-84 [0004]
- *Journal of Immunological Methods*, 2000, vol. 234, 123-135 [0004]
- *Journal of Virology*, 1996, vol. 70 (7), 4607-4616 [0004]
- *Journal of Virology*, 1995, vol. 69 (4), 2583-2595 [0004]
- *Gene*, 1991, vol. 108, 193-200 [0006]
- *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 7380-7384 [0022]
- LOISEL, T.P. et al. *Nature Biotech.*, 1997, vol. 15, 1300-1304 [0033] [0035]
- LUCKOW V.A. ; SUMMERS M.D. *Virol.*, 1988, vol. 167, 56 [0034]
- D. STREHLOW et al. *Proc. Natl. Acad. Sci. USA.*, 2000, vol. 97, 4209-4214 [0035]
- ALBRECHTSEN et al. *J. Virological Methods*, 1990, vol. 28, 245-256 [0036]
- HEWISH et al. *J. Virological Methods*, 1983, vol. 7, 223-228 [0036]
- HJORTH ; MERENO-LOPEZ. *J. Virological Methods*, 1982, vol. 5, 151-158 [0036]
- CROOKS et al. *J. Chrom.*, 1990, vol. 502, 59-68 [0036]
- MENTO S.J. Williamsburg Bioprocessing Conference. Viagene, Inc, 1994 [0036]
- NAJAYOU et al. *J. Virological Methods*, 1991, vol. 32, 67-77 [0036]
- DIACO et al. *J. Gen. Virol.*, 1986, vol. 67, 345-351 [0036]
- FOWLER. *J. Virological Methods*, 1986, vol. 11, 59-74 [0036]
- HARUNA et al. *Virology*, 1961, vol. 13, 264-267 [0036]
- GALFRE, G. ; MILSTEIN, C. *Methods Enzymol.*, 1981, vol. 73, 3-46 [0042]
- BORREBAECK, C.A.K. ; LARRICK, J.W. Therapeutic Monoclonal Antibodies. UK, Macmillan Publishers Ltd, 1990 [0045]
- HUSTON, J.S. *Proc. Natl. Acad. Sci. U.S.A.*, 1988, vol. 85, 5879-5883 [0046]
- SATO, K. et al. *Cancer Res.*, 1993, vol. 53, 851-856 [0050]
- Modern Techniques in Gene Targeting. Yodosha, 2000, 190-207 [0059]